TokenPost·
Xencor Shares Climb 23.94% on XmAb819 Kidney Cancer Results
23.94%
share gain
A Phase 1 study showed a 45.5% response rate in advanced kidney cancer. Xencor plans accelerated discussions with the Food and Drug Administration.
More news
- TokenPostByteDance Launches AI Studio for Short-Drama Production and Regional Visual Remakes
- TokenPostRizwan Ansari's CKB Forecast Sees Potential $0.0760 High by 2030
- TokenPostVerge (XVG) Scenario Puts 2030 Average at $0.14, High at $0.2945
- TokenPostBitcoin Trades at $80,276 as QCP Sets $78,000 Support Level
- TokenPostPepsiCo’s 2025 Revenue Nearly Doubled Coca-Cola’s, but Its Market Cap Was Smaller
- TokenPostBank for International Settlements Says Supply Risks Need Different Fixes